An inventor’s dream is to take a compelling idea the whole way to commercialisation. Dr Roland Buelow was the first scientist to genetically engineer rats. Seeing the benefits in making human antibodies in rats, he filed for patent protection and started the company OMT. Numerous critical choices had to be made to protect the investments in the new technology. For instance, should a patent application be filed early, or should one wait for more data? The inventor himself and his patent attorneys will explain how they successfully managed this balancing act which culminated in the selling of the technology for >100 million dollars to Ligand therapeutics.
Since the value of a biotech start-up company is almost entirely based on the IP-portfolio, the buyer needs to be confident that the patent portfolio is solid. We will discuss to what extent investors are attributing value to companies based on the quality of the underlying patents and how this can be assessed.
Session ID: 21701